Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Mohammed A. Dahab, Hazem A. Mahdy, Hazem Elkady, Mohammed S. Taghour, Alaa Elwan, Mohamed A. Elkady, Elsayed G. E. Elsakka, Eslam B. Elkaeed, Aisha A. Alsfouk, Ibrahim M. Ibrahim, Ahmed M. Metwaly & Ibrahim H. Eissa. (2023) Semi-synthesized anticancer theobromine derivatives targeting VEGFR-2: in silico and in vitro evaluations. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-20.
Read now
Read now
Manuela Tiako Meyo, Jeanne Chen, Francois Goldwasser, Laure Hirsch & Olivier Huillard. (2022) A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma. Therapeutics and Clinical Risk Management 18, pages 683-698.
Read now
Read now
Sanjib Kumar Das, Suman Jyoti Deka, Dipayan Paul, Debmalya Das Gupta, Tridip Jyoti Das, Devendra Kumar Maravi, Hui Tag & Pallabi Kalita Hui. (2022) In-silico based identification of phytochemicals from Houttuynia cordata Thunb. as potential inhibitors for overexpressed HER2 and VEGFR2 cancer genes. Journal of Biomolecular Structure and Dynamics 40:15, pages 6857-6867.
Read now
Read now
Pooria Safarzadeh Kozani, Pouya Safarzadeh Kozani & Fatemeh Rahbarizadeh. (2022) Addressing the obstacles of CAR T cell migration in solid tumors: wishing a heavy traffic. Critical Reviews in Biotechnology 42:7, pages 1079-1098.
Read now
Read now
Ying Zhang, Jia-Yun Zou, Zhe Wang & Ying Wang. (2019) Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer. Cancer Management and Research 11, pages 7787-7803.
Read now
Read now
Articles from other publishers (43)
Iqbal Azad, Tahmeena Khan, Naseem Ahmad, Abdul Rahman Khan & Yusuf Akhter. (2023) Updates on drug designing approach through computational strategies: a review. Future Science OA 9:5.
Crossref
Crossref
Ali M. Alaseem, Khalid Alhazzani, Ahmed Zuwaiel Alanazi, Yasser Alqarni, Mohammad M. Algahtani, Abdullah S. Alhamed, Glowi Alasiri, Fahad T. Alotaibi, Talha Jawaid & Jehad A. Aldali. (2023) Preclinical In Vitro Investigation of MDM2 Inhibition in Combination with Antiangiogenic Therapy for Breast Cancer Treatment. Scientia Pharmaceutica 91:1, pages 12.
Crossref
Crossref
Amr Elagamy, Laila K. Elghoneimy & Reem K. Arafa. 2023. Recent Developments in the Synthesis and Applications of Pyridines. Recent Developments in the Synthesis and Applications of Pyridines
375
410
.
Ryohei Takahashi, Hiroshi Asanuma, Ryuichi Mizuno & Mototsugu Oya. (2022) Current clinical perspective of urological oncology in the adolescent and young adult generation. International Journal of Clinical Oncology 28:1, pages 28-40.
Crossref
Crossref
Suvadeep Mal, Udita Malik, Monalisa Mahapatra, Abhishek Mishra, Dilipkumar Pal & Sudhir K. Paidesetty. (2022) A review on synthetic strategy, molecular pharmacology of indazole derivatives, and their future perspective. Drug Development Research 83:7, pages 1469-1504.
Crossref
Crossref
Firas Obaid Arhema Frejat, Hongjin Zhai, Yaquan Cao, Lihong Wang, Yaser A. Mostafa, Hesham A.M. Gomaa, Bahaa G.M. Youssif & Chunli Wu. (2022) Novel indazole derivatives as potent apoptotic antiproliferative agents by multi-targeted mechanism: Synthesis and biological evaluation. Bioorganic Chemistry 126, pages 105922.
Crossref
Crossref
Daisuke Obinata, Daigo Funakoshi, Fuminori Sakurai, Tsuyoshi Yoshizawa, Junichi Mochida, Kenya Yamaguchi & Satoru Takahashi. (2022) Real-world efficacy of sequential nivolumab for metastatic renal cancer after first-line molecular targeting therapy. Medicine 101:32, pages e29510.
Crossref
Crossref
Ying Fu, Rengui Saxu, Kadir Ahmad Ridwan, Jiaping Yao, Xiaoxuan Chen, Xueping Xu, Weida Zheng, Peng Yu & Yuou Teng. (2022) Losartan Alleviates the Side Effects and Maintains the Anticancer Activity of Axitinib. Molecules 27:9, pages 2764.
Crossref
Crossref
Aleksandra Sochacka-Ćwikła, Marcin Mączyński & Andrzej Regiec. (2022) FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021. Molecules 27:7, pages 2259.
Crossref
Crossref
Nehad M. Ayoub, Sara K. Jaradat, Kamal M. Al-Shami & Amer E. Alkhalifa. (2022) Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches. Frontiers in Pharmacology 13.
Crossref
Crossref
Yaquan Cao, Yingxue Yang, Hongjin Zhai, Jin Wang, Shuo Zhang, Huanhuan Wang, Pu Yang & Chunli Wu. (2022) Synthesis and Antitumor Activity of Novel 5- and 6-Substituted Indazole Derivatives. Chinese Journal of Organic Chemistry 42:2, pages 590.
Crossref
Crossref
SagarBhimrao Bhagat, AmitY Jadhav, SaiprasadV Patil & HanmantVenkatrao Barkate. (2022) Axitinib in management of renal cell carcinoma: Indian perspective. Oncology Journal of India 6:1, pages 14.
Crossref
Crossref
Sagar Bhagat, Nishtha Khatri, Saiprasad Patil & HanmantV Barkate. (2022) Role of axitinib and other tyrosine kinase inhibitors in the management of metastatic renal cell carcinoma. Journal of Current Oncology 5:1, pages 35.
Crossref
Crossref
Aly-Khan A. Lalani, Daniel Y. C. Heng, Naveen S. Basappa, Lori Wood, Nayyer Iqbal, Deanna McLeod, Denis Soulières & Christian Kollmannsberger. (2022) Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review. Therapeutic Advances in Medical Oncology 14, pages 175883592211086.
Crossref
Crossref
Md Sohel, Habiba Sultana, Tayeba Sultana, Md. Al Amin, Suraiya Aktar, Md. Chayan Ali, Zahed Bin Rahim, Md. Arju Hossain, Abdullah Al Mamun, Mohammad Nurul Amin & Raju Dash. (2022) Chemotherapeutic potential of hesperetin for cancer treatment, with mechanistic insights: A comprehensive review. Heliyon 8:1, pages e08815.
Crossref
Crossref
Iago Dillion Lima CavalcantiIago Dillion Lima Cavalcanti. 2022. Chemotherapy Protocols and Infusion Sequence. Chemotherapy Protocols and Infusion Sequence
201
231
.
Marianna Nalli, Michela Puxeddu, Giuseppe La Regina, Stefano Gianni & Romano Silvestri. (2021) Emerging Therapeutic Agents for Colorectal Cancer. Molecules 26:24, pages 7463.
Crossref
Crossref
Jungeun Lim, Hyeri Choi, Jungho Ahn & Noo Li Jeon. (2021) 3D High‐Content Culturing and Drug Screening Platform to Study Vascularized Hepatocellular Carcinoma in Hypoxic Condition. Advanced NanoBiomed Research 1:12.
Crossref
Crossref
Brian I. Rini, Michael B. Atkins, Toni K. Choueiri, Despina Thomaidou, Brad Rosbrook, Maghull Thakur & Thomas E. Hutson. (2021) Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer 19:5, pages e306-e312.
Crossref
Crossref
Tian‐Ji Ji, Bei Feng, Jie Shen, Min Zhang, Yu‐Qing Hu, Ai‐Xia Jiang, Di‐Qi Zhu, Yi‐Wei Chen, Wei Ji, Zhen Zhang, Hao Zhang & Fen Li. (2021) An Avascular Niche Created by Axitinib‐Loaded PCL/Collagen Nanofibrous Membrane Stabilized Subcutaneous Chondrogenesis of Mesenchymal Stromal Cells. Advanced Science 8:20.
Crossref
Crossref
Tasuku Matsuoka & Masakazu Yashiro. (2021) Molecular-targeted therapy toward precision medicine for gastrointestinal caner: Current progress and challenges. World Journal of Gastrointestinal Oncology 13:5, pages 366-390.
Crossref
Crossref
Jinling Qin, Weyland Cheng, Yong-Tao Duan, Hua Yang & Yongfang Yao. (2021) Indazole as a Privileged Scaffold: The Derivatives and their Therapeutic Applications. Anti-Cancer Agents in Medicinal Chemistry 21:7, pages 839-860.
Crossref
Crossref
Vladimir Lazar, Shai Magidi, Nicolas Girard, Alexia Savignoni, Jean-François Martini, Giorgio Massimini, Catherine Bresson, Raanan Berger, Amir Onn, Jacques Raynaud, Fanny Wunder, Ioana Berindan-Neagoe, Marina Sekacheva, Irene Braña, Josep Tabernero, Enriqueta Felip, Angel Porgador, Claudia Kleinman, Gerald Batist, Benjamin Solomon, Apostolia Maria Tsimberidou, Jean-Charles Soria, Eitan Rubin, Razelle Kurzrock & Richard L. Schilsky. (2021) Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. npj Precision Oncology 5:1.
Crossref
Crossref
Wei Wei, Zhihao Liu, Xiuli Wu, Cailing Gan, Xingping Su, Hongyao Liu, Hanyun Que, Qianyu Zhang, Qiang Xue, Lin Yue, Luoting Yu & Tinghong Ye. (2021) Synthesis and biological evaluation of indazole derivatives as anti-cancer agents. RSC Advances 11:26, pages 15675-15687.
Crossref
Crossref
Hermann A.M. Mucke. (2021) Drug Repurposing Patent Applications July–September 2020. ASSAY and Drug Development Technologies 19:3, pages 204-208.
Crossref
Crossref
Hongwei Shi, Yong Xie, Jigui Xu, Jun Zhu, Cong Wang & Hongyan Wang. (2021) Solubility enhancement, solvent effect and thermodynamic analysis of pazopanib in co-solvent mixtures. The Journal of Chemical Thermodynamics 155, pages 106343.
Crossref
Crossref
Yaquan Cao, Chunying Luo, Pu Yang, Pan Li & Chunli Wu. (2020) Indazole scaffold: a generalist for marketed and clinical drugs. Medicinal Chemistry Research 30:3, pages 501-518.
Crossref
Crossref
Jean-François Martini, Elizabeth R. Plimack, Toni K. Choueiri, David F. McDermott, Igor Puzanov, Mayer N. Fishman, Daniel C. Cho, Ulka Vaishampayan, Bradley Rosbrook, Kathrine C. Fernandez, Jamal C. Tarazi, Saby George & Michael B. Atkins. (2020) Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. Clinical Cancer Research 26:21, pages 5598-5608.
Crossref
Crossref
Wenjing Bai, Jianxin Ji, Qiang Huang & Wei Wei. (2020) Synthesis and evaluation of new thiourea derivatives as antitumor and antiangiogenic agents. Tetrahedron Letters 61:40, pages 152366.
Crossref
Crossref
Stefano Fogli, Camillo Porta, Marzia Del Re, Stefania Crucitta, Giulia Gianfilippo, Romano Danesi, Brian I. Rini & Manuela Schmidinger. (2020) Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer Treatment Reviews 84, pages 101966.
Crossref
Crossref
Matilde Merolle, Maria Patrizia Mongiardi, Maurizia Piras, Andrea Levi & Maria Laura Falchetti. (2020) Glioblastoma Cells Do Not Affect Axitinib-Dependent Senescence of HUVECs in a Transwell Coculture Model. International Journal of Molecular Sciences 21:4, pages 1490.
Crossref
Crossref
Pitsiree Praphanwittaya, Phennapha Saokham, Phatsawee Jansook & Thorsteinn Loftsson. (2020) Aqueous solubility of kinase inhibitors: I the effect of hydrophilic polymers on their γ-cyclodextrin solubilization. Journal of Drug Delivery Science and Technology 55, pages 101462.
Crossref
Crossref
Rafaila Rafique, Syed Muhammad Saad, Arshia, Khalid Mohammed Khan, Shahnaz Perveen & Muhammad Taha. (2020) Facile CuCl2·2H2O catalyzed one-pot conversion of dimedone into highly functionalized indazole based N-arylhydrazinecarbothioamides. Journal of Saudi Chemical Society 24:1, pages 92-97.
Crossref
Crossref
Urvi H. Gala, Dave A. Miller & Robert O. WilliamsIIIIII. (2020) Harnessing the therapeutic potential of anticancer drugs through amorphous solid dispersions. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1873:1, pages 188319.
Crossref
Crossref
D. Samuel Metibemu, O. Adeboye Akinloye, A. Jamiu Akamo, D. Ajiboye Ojo, O. Tolulope Okeowo & I. Olaposi Omotuyi. (2019) Exploring receptor tyrosine kinases-inhibitors in Cancer treatments. Egyptian Journal of Medical Human Genetics 20:1.
Crossref
Crossref
Nicola Silvestris, Antonella Argentiero, Laura Cosmai, Camillo Porta, Loreto Gesualdo, Giuliano Brunori, Oronzo Brunetti, Teresa Rampino, Simona Secondino, Gianpiero Rizzo & Paolo Pedrazzoli. (2019) Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa’ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper. Critical Reviews in Oncology/Hematology 140, pages 39-51.
Crossref
Crossref
Maria Patrizia Mongiardi, Giulia Radice, Maurizia Piras, Venturina Stagni, Simone Pacioni, Agnese Re, Sabrina Putti, Fabrizio Ferrè, Antonella Farsetti, Roberto Pallini, Daniela Barilà, Andrea Levi & Maria Laura Falchetti. (2019) Axitinib exposure triggers endothelial cells senescence through ROS accumulation and ATM activation. Oncogene 38:27, pages 5413-5424.
Crossref
Crossref
Robert RoskoskiJr.Jr.. (2019) Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacological Research 144, pages 19-50.
Crossref
Crossref
James W. Mier. (2019) The tumor microenvironment in renal cell cancer. Current Opinion in Oncology 31:3, pages 194-199.
Crossref
Crossref
Robert RoskoskiJr.Jr.. (2018) The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders. Pharmacological Research 133, pages 35-52.
Crossref
Crossref
Na Wei, Jianqing Liang, Shengming Peng, Qiang Sun, Qiuyun Dai & Mingxin Dong. (2018) Design, Synthesis, and Biological Evaluation of Axitinib Derivatives. Molecules 23:4, pages 747.
Crossref
Crossref
Brittni Foster, Danish Zaidi, Tyler Young, Mary Mobley & Bethany Kerr. (2018) CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance. Biomedicines 6:1, pages 31.
Crossref
Crossref
Robert RoskoskiJr.Jr.. (2018) The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders. Pharmacological Research 129, pages 65-83.
Crossref
Crossref